Pushing the threshold: Commending the VeRTEx protocol and considerations for its evolution - 05/06/26
Doi : 10.1016/j.tracli.2026.05.005
Siddharth Mittal ⁎ 
, Shubham Kudalkar, Rachayita Das Chaudhuri
, Shubham Kudalkar, Rachayita Das Chaudhuri Department of Transfusion Medicine, All India Institute of Medical Sciences, Jodhpur 342005, India
⁎ Corresponding author.
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Friday 05 June 2026
Highlights |
• | The 5.0 g/dL transfusion threshold in VeRTEx is biologically justified by converging evidence from experimental anemia studies and real-world clinical observations. |
• | Daily ECG and lactate-ScvO 2 monitoring provide an objective, bedside-actionable safety net appropriate to this degree of practice departure. |
• | Prospective documentation of non-hemoglobin transfusion triggers would help distinguish safety-driven suspensions from behavioral threshold drift in this open-label design. |
• | Secondary clinical outcomes should be interpreted descriptively; the pilot is underpowered to support safety equivalence conclusions. |
Plan
© 2026
Société francophone de transfusion sanguine (SFTS). Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?